Literature DB >> 14687619

All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.

O Bairey1, O Boycov, E Kaganovsky, Y Zimra, M Shaklai, E Rabizadeh.   

Abstract

B-chronic lymphocytic leukemia (B-CLL) cells have a long survival owing to an alteration in the normal pathways of apoptosis. CLL cells have been found to produce and secrete vascular endothelial growth factor (VEGF). In addition to its major role in angiogenesis, VEGF affects cell survival by interfering with apoptosis. The aim of the present study was to investigate the expression of the VEGF receptors VEGFR-1, VEGFR-2, and VEGFR-3 on B-CLL cells, singly and combined. B-CLL cells were isolated from peripheral blood drawn from patients with CLL. Total VEGF receptor, examined in 13 samples by flow cytometry was present in all cases with mean CD19+/VEGF+ expression of 76% (range 52-92%). Specific receptor expression, examined in 27 samples by immunocytochemical methods, was positive for VEGFR-1 in all 27 patients and for VEGFR-2 and VEGFR-3 in 26 (96%). These findings suggest that the VEGF transduction pathway may be very active in CLL cells, and both its paracrine and autocrine pathways may contribute to their enhanced survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687619     DOI: 10.1016/s0145-2126(03)00256-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

2.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

Review 3.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

5.  Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

Authors:  Xavier Badoux; Carlos Bueso-Ramos; David Harris; Ping Li; Zhiming Liu; Jan Burger; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Hum Pathol       Date:  2011-07-05       Impact factor: 3.466

6.  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

Authors:  Tait Shanafelt; Clive Zent; John Byrd; Charles Erlichman; Betsy Laplant; Asish Ghosh; Timothy Call; Miguel Villalona-Calero; Diane Jelinek; Deborah Bowen; Kristina Laumann; Wenting Wu; Curtis Hanson; Neil Kay
Journal:  Leuk Lymphoma       Date:  2010-11-05

Review 7.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

Review 8.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

9.  N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.

Authors:  Neil E Kay; Tait D Shanafelt; Timothy G Call; Wenting Wu; Betsy R Laplant
Journal:  Leuk Lymphoma       Date:  2009-04

10.  Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Khalief E Hamden; Patrick W Ford; Audy G Whitman; Ossie F Dyson; Shi-Yuan Cheng; James A McCubrey; Shaw M Akula
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.